http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-3138891-A1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1ff94e01b3e6fd7179c432fda74796fe |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-2278 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-57563 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-575 |
filingDate | 2020-05-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_053723a71e9ce7ed2e83c9994236c4f8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_78b173272fdf76a6521b79c5f4ff3362 |
publicationDate | 2020-11-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | CA-3138891-A1 |
titleOfInvention | Vasoactive intestinal peptide (vip) for use in the treatment of drug-induced pneumonitis |
abstract | Checkpoint inhibitor-induced pneumonitis (CIP) is characterized clinically by dyspnea, cough and tachypnea. Hypoxia results from a lymphocyte-dominated alveolitis leading to ground glass opacities and consolidations observed by CT scan. Histological findings include lymphocytic infiltrates, granuloma formation and eosinophilic accumulation. In the management of CIP, systemic administration of steroids such as methylprednisolone is the standard therapy. Moreover, CIP in most cases leads to discontinuation of checkpoint inhibitory therapy and steroids limit the therapeutic effect of checkpoint inhibitors resulting in progression of the underlying malignant disease. Therefore, there is a need of other therapeutic options in CIP that ideally could abrogate the alveolar inflammation induced by checkpoint inhibitors without affecting the systemic effect on the immune system. The focus of the present invention is to deliver a solution to that problem by the topic application of VIP (vasoactive intestinal peptide, a peptide of 28 amino acids). A drug for inhalative VIP therapy is commercially available under the name Aviptadil. |
priorityDate | 2019-05-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 81.